Dataset Information


Sexual activity and vaginal symptoms in the postintervention phase of the Women's Health Initiative Hormone Therapy Trials.

ABSTRACT: OBJECTIVE:To assess the impact of discontinuing oral hormone therapy (HT) on sexual activity, vaginal symptoms, and sexual activity components among participants in the estrogen-progestin therapy (EPT) and estrogen therapy (ET) trial of the Women's Health Initiative. METHODS:Surveys were sent postintervention to those who were still taking study pills and agreed to continue in the study when the trials were stopped. Comparisons between former HT and placebo users were accomplished with chi-square tests for categorical variables and t tests for continuous variables. RESULTS:In all, 13,902 women with mean age at survey 69.9 years (EPT trial, women with intact uterus) and 71.7 years (ET trial, women with history of hysterectomy) responded. Prevalence of sexual activity postintervention was not significantly different between former EPT and placebo users (36.0% vs 34.2%; P?=?0.37). Sexual activity of former ET users was 5.6% higher than placebo users (27.6% vs 22.0%; P?=?0.001). The majority of sexually active women overall maintained orgasmic capacity and sexual satisfaction. Former EPT users were 10% to 12% more likely than former placebo users to report decreased desire, arousal, intercourse, climax, and satisfaction with sexual activity, and also increased dryness and dyspareunia upon discontinuing study drugs (P?


PROVIDER: S-EPMC5821577 | BioStudies | 2018-01-01

REPOSITORIES: biostudies

Similar Datasets

1000-01-01 | S-EPMC5655266 | BioStudies
2011-01-01 | S-EPMC3183360 | BioStudies
2012-01-01 | S-EPMC4053113 | BioStudies
2020-01-01 | S-EPMC7687781 | BioStudies
2012-01-01 | S-EPMC3267886 | BioStudies
2010-01-01 | S-EPMC2936672 | BioStudies
2010-01-01 | S-EPMC2821215 | BioStudies
2015-01-01 | S-EPMC5160007 | BioStudies
2011-01-01 | S-EPMC3059400 | BioStudies
2012-01-01 | S-EPMC3328187 | BioStudies